<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141310">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02005783</url>
  </required_header>
  <id_info>
    <org_study_id>DIPE</org_study_id>
    <nct_id>NCT02005783</nct_id>
  </id_info>
  <brief_title>Study of Danggui Buxue Decoction in Preventing Neutropenia</brief_title>
  <acronym>DIPE</acronym>
  <official_title>Adjuvant Treatment of EC/TC Versus EC/TC Plus Danggui Buxue Decoction in Breast Cancer：A Prospective, Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate EC/TC (epirubicin and cyclophosphomide or docetaxel and cyclophosphomide) with
      EC/TC plus DBD (Danggui Buxue Decoction)  in adjuvant treatment of breast cancer patients.
      The aim is to evaluate whether DBD can decrease the incidence of grade 3/4 neutropenia
      induced by EC/TC regimen during chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>incidence of grade 3/4 neutropenia</measure>
    <time_frame>3 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To compare the incidence of grade 3/4 neutropenia between EC/TC arm and EC/TC plus DBD arm in breast cancer adjuvant chemotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>times of grade 3/4 neutropenia per cycle of chemotherapy</measure>
    <time_frame>3 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To compare the times of grade 3/4 neutropenia per cycle of chemotherapy between EC/TC arm and EC/TC plus DBD arm in breast cancer adjuvant chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of febrile neutropenia</measure>
    <time_frame>3 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>to compare incidence of febrile neutropenia between EC/TC arm and EC/TC plus DBD arm in breast cancer adjuvant chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the time to neutropenia recovery</measure>
    <time_frame>2 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>to compare the time to neutropenia recovery between EC/TC arm and EC/TC plus DBD arm in breast cancer adjuvant chemotherapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Grade 3/4 Neutropenia</condition>
  <condition>Febrile Neutropenia</condition>
  <arm_group>
    <arm_group_label>DBD arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epirubicin: 90mg/m2, d1, q3w*4 Cyclophosphamide: 600mg/m2, d1, q3w*4 DBD: one dose of medicine twice per day, orally OR; Docetaxel: 75mg/m2, d1, q3w*4 Cyclophosphamide: 600mg/m2, d1, q3w*4 DBD: one dose of medicine twice per day, orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EC/TC</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Epirubicin: 90mg/m2, d1, q3w*4 Cyclophosphamide: 600mg/m2, d1, q3w*4 OR; Docetaxel: 75mg/m2, d1, q3w*4 Cyclophosphamide: 600mg/m2, d1, q3w*4</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DBD</intervention_name>
    <description>DBD:one dose of medicine twice per day, orally</description>
    <arm_group_label>DBD arm</arm_group_label>
    <other_name>Danggui Buxue Decoction</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <description>Epirubicin:90mg/m2, d1, q3w*4</description>
    <arm_group_label>DBD arm</arm_group_label>
    <arm_group_label>EC/TC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide:600mg/m2, d1, q3w*4</description>
    <arm_group_label>DBD arm</arm_group_label>
    <arm_group_label>EC/TC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel:75mg/m2, d1, q3w*4</description>
    <arm_group_label>DBD arm</arm_group_label>
    <arm_group_label>EC/TC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Women aged ≥18 years and &lt; 70 years; Histologically confirmed invasive breast cancer by
        core needle biopsy, suggested to receive EC/TC regiments for adjuvant chemotherapy by MDT;
        Leukocyte ≥ 3*109/L; Neutrophil ≥ 1.5*109/L; PLT ≥ 100*109/L; Serum AST/SGOT or ALT/AGPT ≤
        2.5 times of upper limit of normal (UNL) range Serum creatinine/BUN ≤ upper limit of
        normal (UNL) range; No dysphagia, be able to take the  Danggui Buxue Decoction(DBD)
        Written informed consent according to the local ethics committee requirements. Has ECOG
        Performance Score 0-1;

        Exclusion Criteria:

        Metastatic breast cancer; Family history of endometrial cancer or any other kind of
        gynecologic cancer; Patients with severe co-morbidity that indicate intolerant to adjuvant
        chemotherapy; patients with psychiatric disorder or other diseases leading to incompliance
        to the therapy; Known severe hypersensitivity to any drugs in this study; Prior adjuvant
        chemotherapy of any kind cancer; Hematologic disorders relative to aplasia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kunwei Shen, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital, Shanghai Jiaotong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaosong Chen, Dr</last_name>
    <phone>64370045</phone>
    <phone_ext>602205</phone_ext>
    <email>chenxiaosong0156@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaosong Chen, Dr.</last_name>
      <phone>0086-64370045</phone>
      <phone_ext>602205</phone_ext>
      <email>chenxiaosong0156@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Kunwei Shen, Pro.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 9, 2013</lastchanged_date>
  <firstreceived_date>December 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Kunwei Shen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>incidence of grade 3/4 neutropenia</keyword>
  <keyword>incidence of febrile neutropenia</keyword>
  <keyword>time to neutropenia recovery</keyword>
  <keyword>safety</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fever</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
